Research programme: cancer and autoimmune disorders imaging agents - ImaginAb/Duke-NUS

Drug Profile

Research programme: cancer and autoimmune disorders imaging agents - ImaginAb/Duke-NUS

Latest Information Update: 14 Feb 2014

Price : $50

At a glance

  • Originator Duke-NUS Graduate Medical School Singapore; ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 10 Feb 2014 Early research in Autoimmune disorders (diagnosis) in Singapore (Parenteral)
  • 10 Feb 2014 Early research in Cancer (diagnosis) in Singapore (Parenteral)
  • 10 Feb 2014 ImaginAb and the Duke-NUS Graduate Medical School Singapore (Duke-NUS) enter into a partnership to develop in vivo molecular imaging agents for cancer and autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top